GI Malignancies Debate 2023 - Chicago | Combination therapies to treat hepatocellular carcinoma

Ghassan Abou-Alfa, MD, MBA, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses updates on the treatment of primary liver cancer. Professor Abou-Alfa comments on the importance of biopsies before treatment is prescribed, to confirm the disease and understand the genetic make-up. Liver function, as scored by the Child-Pugh system is also identified as being an important factor in deciding how best to treat patients with hepatocellular carcinoma. The use of combination therapies in liver cancer treatment is focused on by Professor Abou-Alfa; the integration of checkpoint inhibitors and anti-angiogenic drugs has been shown to be effective and result in improvements to survival, as presented in the IMbrave150 trial (NCT03434379) which investigated the checkpoint inhibitor, atezolizumab and the anti-angiogenic drug, bevacizumab. Also discussed is the use of first-line therapies such as lenvatinib or sulfatinib, as second-line treatment following a checkpoint inhibitor regimen. This interview took place at the Great Debates and Updates GI malignancies Debate in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.